https://www.selleckchem.com/pr....oducts/rgd-peptide-g
ent-naive patients, including three (11%) with a complete response. In 233 patients with RET fusion-positive NSCLC, common grade 3 or worse treatment-related adverse events were neutropenia (43 patients [18%]), hypertension (26 [11%]), and anaemia (24 [10%]); there were no treatment-related deaths in this population. Pralsetinib is a new, well-tolerated, promising, once-daily oral treatment option for patients with RET fusion-positive NSCLC. Blueprint Medicines. Blueprint Medicines. To manage the HIV epidemic among men who h
Gefällt mir
Kommentar
Teilen
